Model: Young (2- to 4-month-old) and aged (9- to 10-month-old) C57Bl/6JR mice, APP/PS1 mice, and 5xFAD mice 
Dosage: 0.2 mg/mL of doxycycline in drinking water starting at least 7 days before surgery and ceased 2 days before the partial cellular reprogramming window for engram tagging, after which it was immediately reintroduced

Gene Therapy Restores Cognitive Function in Aging and Alzheimer’s Disease

Delivering a gene therapy targeting ensembles of neurons that store memories restores learning and memory capabilities in mouse models of aging and Alzheimer’s disease.

(The study’s principal investigator, Professor Johannes Gräff | 24 Heures)

A partial cellular reprogramming gene therapy targeting memory trace cells restores facets of learning and memory in aged mice and those modeling Alzheimer’s disease.

Brain &amp; Neurons

Participants: Healthy middle-aged adults 
Dosage: 1200 mg/day of NR for 4 weeks

NR (nicotinamide riboside) raises blood NAD+ (nicotinamide adenine dinucleotide) levels more than NMN (nicotinamide mononucleotide) in healthy adults. 

Some of the researchers on the study, Dr. Christian Dölle (left) and Dr. Charalampos Tzoulis (middle) from the University of Bergen in Norway (image: uib.no). 

Implanting DNA “rivers” into older mice significantly extends their lifespan and reduces age-promoting senescent cells in multiple vital organs. 

Professor of Molecular Immunology at Oxford University, and one of the researchers on the study, Dr. Michael Dustin (image: kennedy.ox.ac.uk). 

DNA Repair

Approved Human Study Sets Up Pivotal Test for Aging Theory from Harvard’s David Sinclair

In a major proving ground test for the longevity field, the FDA has given its approval for a human trial for a gene therapy attempting a near-total rejuvenating reset of cells.

(David Sinclair, Michael Ringel, Sharon Rosenzweig-Lipson, and Jerry McLaughlin of Life Biosciences | Longevity.technology)

The FDA has greenlighted Life Biosciences’ first human trial testing whether their gene therapy can confer a near-total rejuvenating reset of cells.

Clinical Trials

Unpublished Results Show NMNH Triples NAD+ in First Human Trial

According to newly released results from a first-of-its-kind clinical trial, reduced nicotinamide mononucleotide (NMNH) triples circulating NAD+ and improves subjective quality of life scores.

(An image of NMN and reduced NMN [known as NMNH] with an additional hydrogen atom | Effepharm)

Results from a first-of-its-kind human trial show that reduced nicotinamide mononucleotide (NMNH) triples circulating NAD+ levels.

Search Result: Liver

Gene Therapy Targeting Memory-Encoding Neurons Restores Cognitive Function in Aging and Alzheimer’s Disease

NR Raises NAD+ Over 2-Fold More than NMN: New Study Comparing NAD+ Precursors

Newly Discovered DNA “Rivers” More Than Double Lifespan: Oxford University

FDA Greenlights Life Biosciences’ Human Study, Setting Up Pivotal Test for Aging Theory from Harvard’s David Sinclair

Unpublished Results Show NMNH Triples NAD+ in First Human Trial